Treatment with statins, which have an anti-inflammatory effect and reduce C-reactive protein levels, have been shown to decrease the risk of periprocedural coronary events.
Research has shown that cryoplasty, a minimally-invasive treatment that utilizes freezing-cold nitrous oxide injected into an angioplasty balloon, appears to be more effective than standard therapies in the treatment of peripheral artery disease in the lower limbs.
A new study has shown that plaque excision with a new device called the SilverHawk is beneficial as a primary therapy in revascularization of lower extremity peripheral arterial disease.
Results are available from the first-ever human trial of a new device that uses radiofrequency energy to close a patent foramen ovale, a flap-like opening between the upper chambers of the heart. PFO closures have been successfully performed for more than 10 years using catheters to insert permanent devices to seal a PFO.
Very promising one-year results from the first study of a new minimally invasive procedure that uses a small clip to help properly close the leaflets of the mitral valve in patients with mitral regurgitation are available.
An encouraging study has shown that transplantation of bone marrow stem cells into the heart improves heart function and blood flow in heart attack patients for up to six months.
Results from the first-in-man trial of a self-contained magnetic resonance imaging catheter designed to evaluate the composition of plaque found in the heart are available.
TCT Hot Topic Press Conferences: Interactive Q&A press briefings to be held on Wednesday, October 25 at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C
A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. Results of this study were published today in The Journal of Clinical Investigation.
Novella Clinical, a Quintiles company (Novella), and the Cardiovascular Research Foundation (CRF) today announced a preferred provider collaboration that will offer a set of clinical trial services to developers of cardiovascular drugs and devices.
The CTO Summit 2015 is a two-day course featuring the latest research and state-of-the-art technologies for chronic total occlusions.
Data from a meta-analysis published today in The Lancet found that extended duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT.
Data from the BRIGHT trial published today in the Journal of the American Medical Association demonstrated that bivalirudin was superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Findings were first reported at last year’s Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).
TCT 2015 (Transcatheter Cardiovascular Therapeutics) is the annual Scientific Symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
TVT 2015 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter, aortic, and mitral valve therapies. This year’s conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world’s leading experts.
Data from the ILUMIEN II trial found that guidance from optimal coherence tomography (OCT) was associated with comparable stent expansion as guidance from intravascular ultrasound (IVUS) in patients undergoing percutaneous coronary intervention (PCI). Results from the study were presented today at EuroPCR 2015, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
Novella Clinical and the CRF Clinical Trials Center will conduct webinar on how medical device developers can avoid the pitfalls and challenges of conducting cardiovascular clinical trials.
The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium.
To honor the life and work of Dr. Michael Davidson, the Cardiovascular Research Foundation (CRF) has partnered with the San Francisco Giants to host the Dr. Michael Davidson 5K Run/Walk during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine.
The Cardiovascular Research Foundation (CRF) announced that Jason Ware has joined the organization as Director, Meeting Planning. In this role, Ware oversees the meeting planning function of the CRF Center for Education. His responsibilities include managing a staff of meeting planners and working with vendors and internal resources to execute the logistics for CRF educational meetings throughout the year.
CRF has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the TCT 2015 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 in San Francisco, California.
Noteworthy data will be presented at Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium next month on several trials examining the use of cardiovascular stents (or “scaffolds”) that are absorbed back into the body over time.
The Cardiovascular Research Foundation (CRF) announced today that Shelley Wood will join the organization as Editorial Director on October 15. Ms. Wood will lead CRF’s editorial services department and be responsible for developing original, thought-provoking, and clinically relevant content for TCTMD, the leading online resource for cutting-edge news and information in interventional cardiovascular medicine. She will also play an integral role in ongoing enhancements of the TCTMD website.
The Cardiovascular Research Foundation (CRF) has joined #GivingTuesday, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide. This year 100% of the donations to CRF made on Giving Tuesday will go directly to the CRF Fellows Fund, which was established to mentor the next generation of cardiovascular researchers and provide financial support for the rapid advancement of breakthrough treatments needed in the fight against heart disease, the #1 killer of men and women worldwide.
The Cardiovascular Research Foundation (CRF) is pleased to announce that Michael O’Riordan joins the organization today as Senior Editorial Journalist for TCTMD, the leading online resource for cutting-edge news and information in interventional cardiovascular medicine.
The CTO Summit 2016 is a two-day course featuring the latest research and state-of-the-art technologies for chronic total occlusions. This year’s conference will emphasize advanced techniques, evidence-based medicine, and live case transmissions featuring the world’s leading experts in CTO stenting. Sessions showcasing the latest research on CTOs will focus on procedural outcomes, registry updates, and new stent technologies.
The Cardiovascular Research Foundation (CRF) is excited to announce the launch of TCTMD’s new podcast network, the Pulse of Cardiology. TCTMD is the leading online resource for cutting-edge news and information in interventional cardiovascular medicine, and beyond.
Physicians and fellows from the Cardiovascular Research Foundation (CRF) will be presenting abstracts at the American College of Cardiology 65th Annual Scientific Session taking place April 2-4, 2016 at McCormick Place in Chicago, IL. They will be sharing the latest data on drug-eluting stents, imaging technologies, dual antiplatelet therapy, transcatheter aortic valve replacement, and bioresorbable vascular scaffolds.
The Cardiovascular Research Foundation (CRF) announced today that Daniel Burkhoff, MD, PhD, has returned to the organization as Director of Heart Failure, Hemodynamics and Circulatory Support in the CRF Clinical Trials Center (CTC).
The Cardiovascular Research Foundation (CRF), a nonprofit organization dedicated to heart disease research and education, launched a new logo and website today.
The Cardiovascular Research Foundation (CRF), a nonprofit organization dedicated to heart disease research and education, has announced it will be moving its corporate office to a new location in midtown Manhattan.
TVT 2016 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. This year’s conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world’s leading experts.
TCT (Transcatheter Cardiovascular Therapeutics), is the annual Scientific Symposium of the Cardiovascular Research Foundation (CRF). It is the world’s premier educational meeting specializing in interventional cardiovascular medicine and attracts nearly 12,000 attendees from all over the world. Every year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.
Earvin “Magic” Johnson will be a special keynote speaker at TCT 2016 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine, attracting nearly 12,000 attendees from all over the world.
The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.
The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2 in Washington, DC.
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF) will feature a number of first-in-human and early feasibility trials that could impact future clinical practice. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.
The Cardiovascular Research Foundation (CRF) is pleased to announce the launch of the new TCTMD (www.tctmd.com), the leading online resource for cutting-edge news and information in interventional cardiology and beyond.
The Cardiovascular Research Foundation (CRF) is pleased to announce the launch of a new international journal focusing on the diagnosis and treatment of structural heart disease and the importance of the heart team in managing these disorders.
The large multinational randomized BIONICS study found that a novel ridaforolimus-eluting stent (BioNIR) was non-inferior to a zotarolimus-eluting stent (Resolute) for one-year clinical outcomes in a broad, less selected ‘more comers’ population. Results of this trial will be submitted to the FDA for U.S. approval of this novel drug-eluting stent.
Although percutaneous coronary intervention (PCI) is most commonly guided by angiography alone, results from a new study investigating adjunctive imaging modalities showed that the use of a novel optical coherence tomography (OCT)-based stent sizing strategy results in similar minimal stent area (MSA) compared to intravascular ultrasound (IVUS)-guided PCI. Imaging-guided PCI (with both OCT and IVUS) also resulted in improved stent expansion and acute stent-based procedural success compared to angiography-guided PCI.
Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in treating an all-comers population with a high proportion of patients with acute coronary syndromes.
The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high bleeding risk patients treated with one month of dual antiplatelet therapy (DAPT), found that a polymer-free drug-coated stent (DCS) remained both significantly safer and more effective than the comparator bare-metal stent (BMS) used in the trial.
A large-scale randomized trial examining percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) in patients with left main coronary artery disease (LMCAD) and low-intermediate SYNTAX scores found that there was no significant difference in three-year outcomes between the two treatments, with a reduction in 30-day major adverse events with PCI.
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. Findings from the Nordic–Baltic–British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.
A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared with historical zotarolimus-eluting stent (Resolute) data. In addition, there was no binary restenosis, and a high degree of early stent strut coverage with minimal malapposition.
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) featured a number of first report investigations on novel stents that could become the next generation of bioresorbable stents in patients.
A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device during transcatheter aortic valve replacement (TAVR) found that the device was safe but did not meet the primary efficacy endpoint of reduction in median new lesion volume in protected territories assessed by MRI at 2-7 days. In addition, neurocognitive function was not significantly improved.
Patients with severe aortic stenosis (AS) at intermediate surgical risk, and who are treated with transcatheter aortic valve replacement (TAVR) had improved health status at one month compared with surgical aortic valve replacement (SAVR) but two-year quality of life outcomes were similar. Prior studies have shown that TAVR results in an early quality of life (QoL) benefit in patients at high surgical risk; however, the effect of TAVR versus. SAVR on QoL in intermediate risk patients was unknown prior to this study.
A substudy of the PARTNER I Trial and Continued Access Registry found that hemodynamic trends in patients who received transcatheter aortic valve replacement (TAVR) showed excellent durability without significant structural valve deterioration at five years. The trial represents the largest to-date longitudinal analysis of echocardiographic hemodynamic parameters systematically assessed by a core laboratory.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right